Cailianshe reported on February 21 that Kip Biologics announced that recently, the company and its wholly-owned subsidiary Kip Pharmaceuticals, Kepu Chemicals, and holding subsidiary Shanghai Kepu Laboratory received the "Notice of Granting Invention Patents" issued by National Intellectual Property Office . The invention is called a new coronavirus, A and B influenza and respiratory syncytial virus detection kit.
According to public information, Kaipu is a domestic developer and supplier of nucleic acid molecular diagnostic products, focusing on the research, development, production and sales of nucleic acid diagnostic related products such as molecular diagnostic reagents and molecular diagnostic supporting instruments, and providing related services. In 2016, Cappu's "Human Papillomavirus Genotyping Test Kit and Its Gene Chip Preparation Method (ZL200710030723.6)" won the 18th China Invention Patent Gold Award, representing the advanced level of independent innovation in HPV detection in China. On April 12, 2017, Kepu Biotech (300639) issued its shares for the initial public offering and listed on the GEM.
Based on the significant achievements in the industrialization of molecular diagnosis, Kepu Group has established more than 25 molecular medical laboratory institutes in Hong Kong and key cities across the country. With the brand image of "Kepu Medical Testing, Nucleic Acid Diagnosis Expert", it will serve advanced molecular diagnostic technology to primary medical institutions across the country, expanding the company's business to the downstream industrial chain, realizing the integrated business model of "platform + reagent + service".
query smart bud data shows that the publication number of the detection kit patent is "CN112342315A", and is called "a new coronavirus, influenza A and B and respiratory syncytial virus detection kit". According to the patent abstract, the present invention discloses a new coronavirus, influenza A and B and respiratory syncytial virus detection kit. The present invention combines primer probe design and optimization exploration of the corresponding detection system to develop a set of novel coronavirus (2019‑nCoV/SARS‑CoV‑2), influenza A virus (FluA), influenza B virus (FluB) and respiratory syncytial virus (RSV) nucleic acid combination combination primers and probes and combined with nucleic acid detection kits. This kit has the advantages of high detection sensitivity, good repeatability, false negative and low false positive . It can effectively distinguish new coronavirus infection from common viral cold and respiratory syncytial virus caused by respiratory infection , thereby achieving accurate diagnosis and subsequent precise treatment of patients.
